AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Government health plans in the U.S. provide significant coverage for new weight-loss drugs, overshadowing private insurers.

which treat diabetes and obesity, respectively. While these two medicines are grabbing most of the attention, it's worth ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access to Novo Nordisk's Wegovy or Eli Lilly's Zepbound, according to the AXIACI ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...